Keytruda, 25 mg/ml concentrate for solution for infusion, 1 Vial of 4ml, MSD
Price: 3800 $ + shipping
e-mail: sales@gerovital-gh3.com
Bucharest, Romania
Indications:
KEYTRUDA contains the active substance pembrolizumab, which is a monoclonal antibody.
KEYTRUDA works by helping your immune system fight cancer.
KEYTRUDA is used in adults to treat:
• a type of skin cancer called melanoma
• a type of lung cancer called non-small cell lung cancer
• a type of cancer called classic Hodgkin's lymphoma
• a type of cancer called bladder cancer (urothelial carcinoma)
• a type of head and neck cancer called squamous cell carcinoma of the head and neck
• a type of kidney cancer called renal carcinoma
• a type of cancer that has been shown to have high-grade microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR) in the colon or rectum (called colorectal cancer), uterus (called c cancer endometrial), stomach (called gastric cancer), small intestine (called small bowel cancer) or in the bile duct or gallbladder (called biliary tract cancer)
• a type of cancer called esophageal carcinoma
• a type of cancer called triple negative breast cancer
• a type of uterine cancer called endometrial carcinoma
• a type of cancer called cervical cancer
• a type of stomach cancer called gastric or gastroesophageal junction adenocarcinoma
• a type of cancer of the bile duct or gallbladder called biliary tract carcinoma
KEYTRUDA is used in children and adolescents:
• aged 3 years and over to treat a type of cancer called classical Hodgkin's lymphoma
• aged 12 and over to treat a type of cancer called melanoma.
Patients are given KEYTRUDA when their cancer has spread or cannot be removed by surgery.
Patients are given KEYTRUDA after surgery to remove melanoma, non-small cell lung cancer, or renal cell carcinoma to help prevent the cancer from coming back (adjuvant therapy).
Patients are given KEYTRUDA before surgery (neoadjuvant therapy) to treat non-small cell lung cancer or triple-negative breast cancer and then continue to receive KEYTRUDA after surgery (adjuvant therapy) to help to prevent the recurrence of cancer.
KEYTRUDA can be given in combination with other cancer medicines. It is important that you also read the leaflets of these other medicines. If you have any questions about these medicines, talk to your doctor.
Contraindications:
You should not be given KEYTRUDA:
- if you are allergic to pembrolizumab or any of the other components of this medicine.
Precautions:
Talk to your doctor or pharmacist before you are given KEYTRUDA.
Pregnancy and breast-feeding:
Task:
- You should not use KEYTRUDA if you are pregnant, unless your doctor specifically advises you to do so.
- If you are pregnant, think you might be pregnant or intend to become pregnant, tell
your doctor.
- KEYTRUDA may harm or cause death to your unborn baby.
- If you are a woman of childbearing potential, you must use adequate contraception during treatment with KEYTRUDA and for at least 4 months after the last dose.
breast-feeding
- If you are breastfeeding, tell your doctor.
- Do not breast-feed during treatment with KEYTRUDA.
- It is not known whether KEYTRUDA passes into breast milk
Driving vehicles and using machines:
KEYTRUDA has a minor influence on your ability to drive or use machines. Feeling dizzy, tired, or weak are possible side effects of KEYTRUDA. Do not drive or operate machinery after being given KEYTRUDA unless you are sure you are feeling well.
Mode of administration:
KEYTRUDA will be given to you in a hospital or clinic under the supervision of a doctor experienced in the treatment of cancer.
- The recommended dose of KEYTRUDA in adults is either 200 mg every 3 weeks or 400 mg every 6 weeks.
- The recommended dose of KEYTRUDA in children and adolescents aged 3 years and over with classical Hodgkin's lymphoma and in adolescents aged 12 years and over with melanoma is 2 mg/kg body weight (up to a maximum of 200 mg) at 3 week intervals.
- Your doctor will give you KEYTRUDA as an infusion into a vein (intravenously) over about 30 minutes.
- Your doctor will decide how many administrations of the treatment you need.
If you have any further questions about this medicine, ask your doctor or pharmacist.
Composition:
- The active substance is pembrolizumab.
One 4 ml vial contains pembrolizumab 100 mg.
Each ml of concentrate contains 25 mg of pembrolizumab.
- The other ingredients are L-histidine, L-histidine hydrochloride monohydrate, sucrose, polysorbate 80 and water for injections
Presentation:
1 vial - 4ml (25mg/ml)